Zenapax (daclizumab)
- Region
- 🇪🇺 EU
- Active substance
- daclizumab
- Company
- Roche Registration Ltd.
- Status
- Withdrawn
- Therapeutic area
- Graft Rejection; Kidney Transplantation
- EU approval
- Fri 26 Feb 1999
- Application
- EMEA/H/C/000198
- ATC
- L04AA08
- Official record
- www.ema.europa.eu
Indication
Zenapax is indicated for the prophylaxis of acute organ rejection in de novo allogenic renal transplantation and is to be used concomitantly with an immunosuppressive regimen, including cyclosporine and corticosteroids in patients who are not highly immunised.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Zinbryta Withdrawn · Biogen Idec Ltd
Follow Zenapax
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.